Atea’s BEM/RZR Drug-Interaction Study Reaches Completion: What Investors Should Watch Next
at www.tipranks.com (Wed, 28-Oct 12:31 PM)
Atea’s BEM/RZR Achieves High Cure Rates Across HCV Genotypes—Potential to Shorten Treatment for Majority of Patients
Market Chameleon (Tue, 28-Jul 7:53 AM)
